Corporate ActionJun 25, 2026, 05:12 PM
Spero Therapeutics Increases Authorized Shares to 240M; Approves 2026 Stock Plan
AI Summary
Spero Therapeutics' stockholders approved an amendment to the company's Certificate of Incorporation, doubling the authorized common stock from 120 million to 240 million shares. Additionally, the 2026 Stock Incentive Plan, allowing for the issuance of up to 12,895,866 shares, was approved. These actions took place at the Annual Meeting on June 23, 2026, where stockholders also re-elected two directors, ratified the independent auditor, and approved executive compensation.
Key Highlights
- Stockholders approved increasing authorized common stock from 120,000,000 to 240,000,000 shares.
- The 2026 Stock Incentive Plan was approved, allowing for the issuance of up to 12,895,866 shares.
- Milind Deshpande and Kathleen Tregoning were reelected as Class III directors.
- PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2026.
- The advisory vote on executive compensation was approved by stockholders.
Price Impact
More from SPRO